Dordaviprone

Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively.

Jazz Pharmaceuticals announces acquisition of Chimerix for $935 million, gaining dordaviprone, a first-in-class treatment for rare H3 K27M-mutant diffuse glioma with FDA Priority Review status.

Q32 Bio's bempikibart showed promise in Phase IIa trial for alopecia areata (AA), achieving a 16% mean reduction in SALT score at week 24 compared to placebo.

Chimerix has submitted a New Drug Application (NDA) to the FDA for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma, a highly aggressive brain tumor.

The FDA has accepted and granted priority review to Chimerix's new drug application for dordaviprone, a treatment for recurrent H3 K27M-mutant diffuse glioma.